{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T10:47:28Z","timestamp":1758970048257,"version":"3.37.3"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,11,29]],"date-time":"2017-11-29T00:00:00Z","timestamp":1511913600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2017,11,29]],"date-time":"2017-11-29T00:00:00Z","timestamp":1511913600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1TR001422"],"award-info":[{"award-number":["UL1TR001422"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12890-017-0503-6","type":"journal-article","created":{"date-parts":[[2017,11,29]],"date-time":"2017-11-29T11:36:44Z","timestamp":1511955404000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Antibiotic duration and changes in FEV1 are not associated with time until next exacerbation in adult cystic fibrosis: a single center study"],"prefix":"10.1186","volume":"17","author":[{"given":"Julia C.","family":"Espel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah L.","family":"Palac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne F.","family":"Cullina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandria P.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanna A.","family":"McColley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle H.","family":"Prickett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1534-5629","authenticated-orcid":false,"given":"Manu","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,11,29]]},"reference":[{"issue":"2","key":"503_CR1","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1378\/chest.126.2.412","volume":"126","author":"DB Rosenbluth","year":"2004","unstructured":"Rosenbluth DB, Wilson K, Ferkol T, Schuster DP. Lung function decline in cystic fibrosis patients and timing for lung transplantation referral. Chest. 2004;126(2):412\u20139.","journal-title":"Chest"},{"issue":"4","key":"503_CR2","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1136\/thx.2006.060889","volume":"62","author":"CH Goss","year":"2007","unstructured":"Goss CH, Burns JL. Exacerbations in cystic fibrosis. 1: epidemiology and pathogenesis. Thorax. 2007;62(4):360\u20137.","journal-title":"Thorax"},{"issue":"3","key":"503_CR3","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.rmed.2008.09.024","volume":"103","author":"A Amadori","year":"2009","unstructured":"Amadori A, Antonelli A, Balteri I, Schreiber A, Bugiani M, De Rose V. Recurrent exacerbations affect FEV(1) decline in adult patients with cystic fibrosis. Respir Med. 2009;103(3):407\u201313.","journal-title":"Respir Med"},{"issue":"8","key":"503_CR4","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1136\/thx.2011.161117","volume":"66","author":"K de Boer","year":"2011","unstructured":"de Boer K, Vandemheen KL, Tullis E, Doucette S, Fergusson D, Freitag A, Paterson N, Jackson M, Lougheed MD, Kumar V, et al. Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis. Thorax. 2011;66(8):680\u20135.","journal-title":"Thorax"},{"issue":"4","key":"503_CR5","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/ppul.21374","volume":"46","author":"DB Sanders","year":"2011","unstructured":"Sanders DB, Bittner RC, Rosenfeld M, Redding GJ, Goss CH. Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis. Pediatr Pulmonol. 2011;46(4):393\u2013400.","journal-title":"Pediatr Pulmonol"},{"issue":"5","key":"503_CR6","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1164\/rccm.200909-1421OC","volume":"182","author":"DB Sanders","year":"2010","unstructured":"Sanders DB, Bittner RC, Rosenfeld M, Hoffman LR, Redding GJ, Goss CH. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med. 2010;182(5):627\u201332.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"503_CR7","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1378\/chest.121.1.64","volume":"121","author":"MT Britto","year":"2002","unstructured":"Britto MT, Kotagal UR, Hornung RW, Atherton HD, Tsevat J, Wilmott RW. Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. Chest. 2002;121(1):64\u201372.","journal-title":"Chest"},{"issue":"1","key":"503_CR8","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1164\/rccm.200409-1244OC","volume":"172","author":"CJ Dobbin","year":"2005","unstructured":"Dobbin CJ, Bartlett D, Melehan K, Grunstein RR, Bye PT. The effect of infective exacerbations on sleep and neurobehavioral function in cystic fibrosis. Am J Respir Crit Care Med. 2005;172(1):99\u2013104.","journal-title":"Am J Respir Crit Care Med"},{"issue":"18","key":"503_CR9","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","volume":"365","author":"BW Ramsey","year":"2011","unstructured":"Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Drevinek P, Griese M, McKone EF, Wainwright CE, Konstan MW, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365(18):1663\u201372.","journal-title":"N Engl J Med"},{"issue":"2","key":"503_CR10","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1378\/chest.11-0917","volume":"141","author":"MD Parkins","year":"2012","unstructured":"Parkins MD, Rendall JC, Elborn JS. Incidence and risk factors for pulmonary exacerbation treatment failures in patients with cystic fibrosis chronically infected with Pseudomonas Aeruginosa. Chest. 2012;141(2):485\u201393.","journal-title":"Chest"},{"issue":"4","key":"503_CR11","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S0022-3476(99)70197-6","volume":"134","author":"AL Smith","year":"1999","unstructured":"Smith AL, Doershuk C, Goldmann D, Gore E, Hilman B, Marks M, Moss R, Ramsey B, Redding G, Rubio T, et al. Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis. J Pediatr. 1999;134(4):413\u201321.","journal-title":"J Pediatr"},{"issue":"4","key":"503_CR12","first-page":"522","volume":"54","author":"PA Flume","year":"2009","unstructured":"Flume PA, Robinson KA, O'Sullivan BP, Finder JD, Vender RL, Willey-Courand DB, White TB, Marshall BC. Cystic fibrosis pulmonary guidelines: airway clearance therapies. Respir Care. 2009;54(4):522\u201337.","journal-title":"Respir Care"},{"issue":"129","key":"503_CR13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1183\/09059180.00006512","volume":"22","author":"JM Bhatt","year":"2013","unstructured":"Bhatt JM. Treatment of pulmonary exacerbations in cystic fibrosis. Eur Respir Rev. 2013;22(129):205\u201316.","journal-title":"Eur Respir Rev"},{"issue":"1","key":"503_CR14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1177\/1479972307085635","volume":"5","author":"NA Jarad","year":"2008","unstructured":"Jarad NA, Giles K. Risk factors for increased need for intravenous antibiotics for pulmonary exacerbations in adult patients with cystic fibrosis. Chron Respir Dis. 2008;5(1):29\u201333.","journal-title":"Chron Respir Dis"},{"issue":"1","key":"503_CR15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1177\/1479972311433575","volume":"9","author":"IM Sequeiros","year":"2012","unstructured":"Sequeiros IM, Jarad N. Factors associated with a shorter time until the next pulmonary exacerbation in adult patients with cystic fibrosis. Chron Respir Dis. 2012;9(1):9\u201316.","journal-title":"Chron Respir Dis"},{"issue":"6","key":"503_CR16","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.jcf.2015.02.007","volume":"14","author":"DR VanDevanter","year":"2015","unstructured":"VanDevanter DR, Pasta DJ, Konstan MW. Treatment and demographic factors affecting time to next pulmonary exacerbation in cystic fibrosis. J Cyst Fibros. 2015;14(6):763\u20139.","journal-title":"J Cyst Fibros"},{"issue":"3","key":"503_CR17","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jcf.2015.10.006","volume":"15","author":"DR VanDevanter","year":"2016","unstructured":"VanDevanter DR, Morris NJ, Konstan MW. IV-treated pulmonary exacerbations in the prior year: an important independent risk factor for future pulmonary exacerbation in cystic fibrosis. J Cyst Fibros. 2016;15(3):372\u20139.","journal-title":"J Cyst Fibros"},{"issue":"1","key":"503_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000087686","volume":"73","author":"N Lechtzin","year":"2006","unstructured":"Lechtzin N, John M, Irizarry R, Merlo C, Diette GB, Boyle MP. Outcomes of adults with cystic fibrosis infected with antibiotic-resistant Pseudomonas Aeruginosa. Respiration. 2006;73(1):27\u201333.","journal-title":"Respiration"},{"issue":"1","key":"503_CR19","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ijantimicag.2010.02.018","volume":"36","author":"EP O'Donnell","year":"2010","unstructured":"O'Donnell EP, Scarsi KK, Scheetz MH, Postelnick MJ, Cullina J, Jain M. Risk factors for aminoglycoside ototoxicity in adult cystic fibrosis patients. Int J Antimicrob Agents. 2010;36(1):94\u20135.","journal-title":"Int J Antimicrob Agents"},{"issue":"9","key":"503_CR20","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1164\/rccm.200812-1845PP","volume":"180","author":"PA Flume","year":"2009","unstructured":"Flume PA, Mogayzel PJ Jr, Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, Marshall BC, Clinical Practice Guidelines for Pulmonary Therapies C. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med. 2009;180(9):802\u20138.","journal-title":"Am J Respir Crit Care Med"},{"key":"503_CR21","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/1465-9921-11-137","volume":"11","author":"DR VanDevanter","year":"2010","unstructured":"VanDevanter DR, O'Riordan MA, Blumer JL, Konstan MW. Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations. Respir Res. 2010;11:137.","journal-title":"Respir Res"},{"key":"503_CR22","doi-asserted-by":"crossref","unstructured":"Heltshe SL, Goss CH, Thompson V, Sagel SD, Sanders DB, Marshall BC, Flume PA. Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis. Thorax. 2016;71(3):223\u201329.","DOI":"10.1136\/thoraxjnl-2014-206750"},{"issue":"9484","key":"503_CR23","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/S0140-6736(05)67060-2","volume":"366","author":"SD Aaron","year":"2005","unstructured":"Aaron SD, Vandemheen KL, Ferris W, Fergusson D, Tullis E, Haase D, Berthiaume Y, Brown N, Wilcox P, Yozghatlian V, et al. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet. 2005;366(9484):463\u201371.","journal-title":"Lancet"},{"issue":"1","key":"503_CR24","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1164\/ajrccm.159.1.9712108","volume":"159","author":"JL Hankinson","year":"1999","unstructured":"Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med. 1999;159(1):179\u201387.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"503_CR25","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1214\/aos\/1176345976","volume":"10","author":"PK Andersen","year":"1982","unstructured":"Andersen PK, Gill RD. Cox's regression model for counting processes: a large sample study. Ann Stat. 1982;10(4):1100\u201320.","journal-title":"Ann Stat"},{"key":"503_CR26","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1186\/1475-2875-13-293","volume":"13","author":"I Sagara","year":"2014","unstructured":"Sagara I, Giorgi R, Doumbo OK, Piarroux R, Gaudart J. Modelling recurrent events: comparison of statistical models with continuous and discontinuous risk intervals on recurrent malaria episodes data. Malar J. 2014;13:293.","journal-title":"Malar J"},{"issue":"2","key":"503_CR27","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/biomet\/68.2.373","volume":"68","author":"RLWB Perntice","year":"1981","unstructured":"Perntice RLWB, Peterson AV. On the regression analysis for multivariate failure time data. Biometrika. 1981;68(2):373\u20139.","journal-title":"Biometrika"},{"key":"503_CR28","volume-title":"Patient registry annual report 2014","author":"Foundation CF","year":"2014","unstructured":"Foundation CF. Patient registry annual report 2014. Bethesda: Cystic Fibrosis Foundation; 2014."},{"issue":"5","key":"503_CR29","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/ppul.23147","volume":"50","author":"MS Schechter","year":"2015","unstructured":"Schechter MS, Regelmann WE, Sawicki GS, Rasouliyan L, VanDevanter DR, Rosenfeld M, Pasta D, Morgan W, Konstan MW. Antibiotic treatment of signs and symptoms of pulmonary exacerbations: a comparison by care site. Pediatr Pulmonol. 2015;50(5):431\u201340.","journal-title":"Pediatr Pulmonol"},{"issue":"4","key":"503_CR30","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1177\/1479972312445903","volume":"9","author":"IM Sequeiros","year":"2012","unstructured":"Sequeiros IM, Jarad NA. Extending the course of intravenous antibiotics in adult patients with cystic fibrosis with acute pulmonary exacerbations. Chron Respir Dis. 2012;9(4):213\u201320.","journal-title":"Chron Respir Dis"},{"issue":"6","key":"503_CR31","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.jcf.2015.07.010","volume":"14","author":"V Waters","year":"2015","unstructured":"Waters V, Stanojevic S, Klingel M, Chiang J, Sonneveld N, Kukkar R, Tullis E, Ratjen F. Prolongation of antibiotic treatment for cystic fibrosis pulmonary exacerbations. J Cyst Fibros. 2015;14(6):770\u20136.","journal-title":"J Cyst Fibros"},{"issue":"3","key":"503_CR32","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1128\/AAC.01212-07","volume":"52","author":"D Hocquet","year":"2008","unstructured":"Hocquet D, Muller A, Blanc K, Plesiat P, Talon D, Monnet DL, Bertrand X. Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas Aeruginosa. Antimicrob Agents Chemother. 2008;52(3):1173\u20135.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9281","key":"503_CR33","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/S0140-6736(01)05714-2","volume":"358","author":"AM Jones","year":"2001","unstructured":"Jones AM, Govan JR, Doherty CJ, Dodd ME, Isalska BJ, Stanbridge TN, Webb AK. Spread of a multiresistant strain of Pseudomonas Aeruginosa in an adult cystic fibrosis clinic. Lancet. 2001;358(9281):557\u20138.","journal-title":"Lancet"},{"issue":"2","key":"503_CR34","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/ppul.21526","volume":"47","author":"SL Vandenbranden","year":"2012","unstructured":"Vandenbranden SL, McMullen A, Schechter MS, Pasta DJ, Michaelis RL, Konstan MW, Wagener JS, Morgan WJ, McColley SA. Lung function decline from adolescence to young adulthood in cystic fibrosis. Pediatr Pulmonol. 2012;47(2):135\u201343.","journal-title":"Pediatr Pulmonol"},{"issue":"5","key":"503_CR35","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jcf.2012.03.009","volume":"11","author":"MW Konstan","year":"2012","unstructured":"Konstan MW, Wagener JS, Vandevanter DR, Pasta DJ, Yegin A, Rasouliyan L, Morgan WJ. Risk factors for rate of decline in FEV1 in adults with cystic fibrosis. J Cyst Fibros. 2012;11(5):405\u201311.","journal-title":"J Cyst Fibros"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-017-0503-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12890-017-0503-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-017-0503-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T11:20:19Z","timestamp":1589455219000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-017-0503-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,29]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["503"],"URL":"https:\/\/doi.org\/10.1186\/s12890-017-0503-6","relation":{},"ISSN":["1471-2466"],"issn-type":[{"type":"electronic","value":"1471-2466"}],"subject":[],"published":{"date-parts":[[2017,11,29]]},"assertion":[{"value":"19 December 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Patients enrolling in the CFFPR have given informed consent for observational research using their data. The study was approved by Northwestern IRB.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"160"}}